TY - JOUR
T1 - In danger
T2 - HIV vaccine research and development in Europe
AU - Tatoud, Roger
AU - Lévy, Yves
AU - le Grand, Roger
AU - Alcami, Jose
AU - Barbareschi, Giorgio
AU - Brander, Christian
AU - Cara, Andrea
AU - Combadière, Behazine
AU - Dabis, François
AU - Fidler, Sarah
AU - Hanke, Tomáš
AU - Herrera, Carolina
AU - Karlsson Hedestam, Gunilla B.
AU - Kuipers, Hester
AU - McCormack, Sheena
AU - Moog, Christiane
AU - Pantaleo, Giuseppe
AU - Richert, Laura
AU - Sanders, Rogier W.
AU - Shattock, Robin
AU - Streeck, Hendrik
AU - Thiebaut, Rodolphe
AU - Trkola, Alexandra
AU - Üeberla, Klaus
AU - van Gills, Marit J.
AU - Wagner, Ralf
AU - Weissenhorn, Winfried
AU - Yazdanpanah, Yazdan
AU - Scarlatti, Gabriella
AU - Lelièvre, Jean Daniel
N1 - Publisher Copyright:
© 2025 Tatoud et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025/4/1
Y1 - 2025/4/1
N2 - Highly effective antiretroviral-based HIV prevention plays an important role in ending the global HIV/AIDS epidemic. However, the sustainable control of the epidemic is hampered by unequal access to prevention options, including HIV testing, alongside with drug resistance and ongoing barriers to accessing sustainable HIV treatment. Therefore, an HIV vaccine, combined with effective prevention and treatment, remains an absolute necessity to control the epidemic. Yet, the recent discontinuation of four major vaccine efficacy studies is raising concerns about the future of HIV vaccine research and development globally, and particularly in the European region where funding for vaccine research and development has shrinked. This viewpoint emphasises that supporting HIV vaccine research and development at the European level remains crucial: it is not only necessary to control the epidemic, but it promotes innovation, strengthens health security, epidemic preparedness, and health sovereignty while contributing to the economies of European nations.
AB - Highly effective antiretroviral-based HIV prevention plays an important role in ending the global HIV/AIDS epidemic. However, the sustainable control of the epidemic is hampered by unequal access to prevention options, including HIV testing, alongside with drug resistance and ongoing barriers to accessing sustainable HIV treatment. Therefore, an HIV vaccine, combined with effective prevention and treatment, remains an absolute necessity to control the epidemic. Yet, the recent discontinuation of four major vaccine efficacy studies is raising concerns about the future of HIV vaccine research and development globally, and particularly in the European region where funding for vaccine research and development has shrinked. This viewpoint emphasises that supporting HIV vaccine research and development at the European level remains crucial: it is not only necessary to control the epidemic, but it promotes innovation, strengthens health security, epidemic preparedness, and health sovereignty while contributing to the economies of European nations.
UR - https://www.scopus.com/pages/publications/105002246759
U2 - 10.1371/journal.pgph.0004364
DO - 10.1371/journal.pgph.0004364
M3 - Article
C2 - 40198605
SN - 2767-3375
VL - 5
JO - PLOS global public health
JF - PLOS global public health
IS - 4
M1 - e0004364
ER -
SDG 3 Good Health and Well-being
SDG 5 Gender Equality